Status:
COMPLETED
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Lead Sponsor:
Nicox Ophthalmics, Inc.
Conditions:
Blepharitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD ...
Eligibility Criteria
Inclusion
- documented history of blepharitis and meet qualifying criteria for an acute exacerbation of blepharitis in both eyes at Screening and Baseline/Day 1 Visits
- have a qualifying best-corrected visual acuity
Exclusion
- abnormality of the eyelids or lashes (other than blepharitis), or previous eyelid surgery
- IOP \> 21 mmHg at Screening or Baseline/Day 1 Visits
- use of steroids in the past 30 days or retinoids in the past 12 months
- uncontrolled systemic disease
Key Trial Info
Start Date :
December 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT04675242
Start Date
December 14 2020
End Date
June 30 2021
Last Update
June 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Research Foundation
Newport Beach, California, United States, 92663